Zhiwen Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Zhiwen Zhang has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
Yang Li
Affiliated Hospital of Hubei University of Traditional Chinese Medicine
5 shared publicationsHongyu Yan
The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, CHINA
2 shared publications- Yang Li
Department of Orthopedic Surgery, Hubei Provincial Hospital of Traditional Chinese Medicine /Affiliated Hospital of Hubei University of Chinese Medicine, Wuhan, China
2 shared publications Zhongyuan Liu
Hubei University of Traditional Chinese Medicine
2 shared publications- Bang-Zhi Li
College of Acupuncture and Orthopedics
1 shared publication Bangzhi Li
College of Acupuncture and Orthopedics
1 shared publication
Latest Publications
- Open Access
Identification of Endoplasmic reticulum Homeostasis-associated diagnostic biomarkers for Sarcopenia through integrated Bioinformatics and Experimental Validation
Sarcopenia is an age-related skeletal muscle disorder characterized by progressive loss of muscle mass and function, yet reliable biomarkers for early diagnosis remain limited. Emerging evidence suggests that disruption of endoplasmic reticulum (ER) homeostasis contributes to skeletal muscle aging, however, the diagnostic relevance of ER stress- and reticulophagy-related alterations in sarcopenia remains poorly understood. In this study, three skeletal muscle transcriptomic datasets (GSE25941, GSE28422, and GSE38718) were integrated following batch-effect correction to identify differentially expressed genes (DEGs) between sarcopenic and control samples. DEGs were intersected with ER stress and reticulophagy related gene sets to obtain sarcopenia-associated candidate genes. Subsequently, three machine-learning algorithms, including least absolute shrinkage and selection operator (LASSO), random forest (RF), and support vector machine (SVM), were applied to identify key hub genes. Functional enrichment analyses, transcription factor (TF)-miRNA regulatory network construction, protein-chemical interaction analyses, external validation, nomogram development, and quantitative real-time PCR (qRT-PCR) verification were performed. A total of 236 DEGs were identified, comprising 34 upregulated and 202 downregulated genes. Intersection analysis with 1,772 ER stress and reticulophagy related genes yielded 10 candidate genes, from which five hub genes ( ACTC1 , NPY , CDKN2B , GADD45G , and GRIA1 ) were consistently identified by machine-learning analyses. Functional enrichment analysis indicated significant involvement in extracellular matrix organization, cytokine-cytokine receptor interaction, mitochondrial translation, and respiratory electron transport pathways. Regulatory network analyses further revealed potential interactions with multiple transcription factors, miRNAs, and chemical compounds. In the independent validation cohort (GSE1428), ACTC1 showed strong individual discriminative performance, NPY and GADD45G showed moderate performance, whereas GRIA1 showed limited discrimination and CDKN2B showed near-chance individual performance, whereas the combined gene signature exhibited improved discriminative ability. A predictive nomogram was established. Moreover, qRT-PCR analysis of human skeletal muscle biopsy specimens confirmed significantly increased expression of ACTC1 , NPY , CDKN2B , and GRIA1 , together with decreased expression of GADD45G in sarcopenic muscle tissues compared with controls (all p < 0.05). Collectively, our findings identified a five-gene signature associated with ER stress and reticulophagy related molecular networks in sarcopenia. Although these genes are not established core regulators of ER stress or reticulophagy, they exhibited promising diagnostic value and may reflect ER homeostasis-related molecular alterations during skeletal muscle aging, providing novel biomarkers and potential insights into the molecular basis of sarcopenia.
Open AccessIdentification of Endoplasmic reticulum Homeostasis-associated diagnostic biomarkers for Sarcopenia through integrated Bioinformatics and Experimental Validation
Sarcopenia is an age-related skeletal muscle disorder characterized by progressive loss of muscle mass and function, yet reliable biomarkers for early diagnosis remain limited. Emerging evidence suggests that disruption of endoplasmic reticulum (ER) homeostasis contributes to skeletal muscle aging, however, the diagnostic relevance of ER stress- and reticulophagy-related alterations in sarcopenia remains poorly understood. In this study, three skeletal muscle transcriptomic datasets (GSE25941, GSE28422, and GSE38718) were integrated following batch-effect correction to identify differentially expressed genes (DEGs) between sarcopenic and control samples. DEGs were intersected with ER stress and reticulophagy related gene sets to obtain sarcopenia-associated candidate genes. Subsequently, three machine-learning algorithms, including least absolute shrinkage and selection operator (LASSO), random forest (RF), and support vector machine (SVM), were applied to identify key hub genes. Functional enrichment analyses, transcription factor (TF)-miRNA regulatory network construction, protein-chemical interaction analyses, external validation, nomogram development, and quantitative real-time PCR (qRT-PCR) verification were performed. A total of 236 DEGs were identified, comprising 34 upregulated and 202 downregulated genes. Intersection analysis with 1,772 ER stress and reticulophagy related genes yielded 10 candidate genes, from which five hub genes ( ACTC1 , NPY , CDKN2B , GADD45G , and GRIA1 ) were consistently identified by machine-learning analyses. Functional enrichment analysis indicated significant involvement in extracellular matrix organization, cytokine-cytokine receptor interaction, mitochondrial translation, and respiratory electron transport pathways. Regulatory network analyses further revealed potential interactions with multiple transcription factors, miRNAs, and chemical compounds. In the independent validation cohort (GSE1428), ACTC1 showed strong individual discriminative performance, NPY and GADD45G showed moderate performance, whereas GRIA1 showed limited discrimination and CDKN2B showed near-chance individual performance, whereas the combined gene signature exhibited improved discriminative ability. A predictive nomogram was established. Moreover, qRT-PCR analysis of human skeletal muscle biopsy specimens confirmed significantly increased expression of ACTC1 , NPY , CDKN2B , and GRIA1 , together with decreased expression of GADD45G in sarcopenic muscle tissues compared with controls (all p < 0.05). Collectively, our findings identified a five-gene signature associated with ER stress and reticulophagy related molecular networks in sarcopenia. Although these genes are not established core regulators of ER stress or reticulophagy, they exhibited promising diagnostic value and may reflect ER homeostasis-related molecular alterations during skeletal muscle aging, providing novel biomarkers and potential insights into the molecular basis of sarcopenia.
- Open Access
Decoding Potential Cuproptosis-Related Genes in Sarcopenia: A Multi-Omics Network Analysis
Sarcopenia is a common age-related skeletal muscle disorder that lacks diagnostic and therapeutic options. Emerging evidence suggests that cuproptosis, a copper-dependent form of regulated cell death, contributes to muscle atrophy, yet the underlying associations remain poorly understood. To address this gap, we integrated two GEO datasets (GSE1428 and GSE25941) for differential expression analysis and applied weighted gene co-expression network analysis (WGCNA) to identify disease-related modules. Cuproptosis-related genes (CRGs) from GeneCards database were intersected with DEGs and WGCNA gene modules to obtain sarcopenia-associated cuproptosis DEGs (SAR-CUP DEGs). Functional enrichment was performed using GO, KEGG, GSEA and GSVA. Hub genes were further identified through three machine learning algorithms (LASSO, RF, and SVM). Regulatory networks were constructed via NetworkAnalyst and GeneMANIA database. A diagnostic model was also developed and later validated in an independent dataset (GSE136344). Experimental validation was performed in a D-galactose-induced sarcopenia cell model. We identified 367 DEGs and 7 co-expression modules, among which 14 SAR-CUP DEGs were mainly enriched in mitochondrial energy metabolism pathways. Machine learning methods highlighted SLC25A12 and PABPC4 as hub genes. Regulatory network analysis revealed key modulators, such as FOXC1, miR-16-5p, GOT2, and GOT1. Diagnostic performance analysis demonstrated strong predictive value for SLC25A12 (AUC = 0.879) and PABPC4 (AUC = 0.858), and RT-qPCR confirmed their downregulation in the sarcopenia cell model (p < 0.01). In conclusion, SLC25A12 and PABPC4 are promising biomarkers linking copper metabolism dysregulation with sarcopenia, offering potential targets for diagnosis and therapy.
Open AccessDecoding Potential Cuproptosis-Related Genes in Sarcopenia: A Multi-Omics Network Analysis
Sarcopenia is a common age-related skeletal muscle disorder that lacks diagnostic and therapeutic options. Emerging evidence suggests that cuproptosis, a copper-dependent form of regulated cell death, contributes to muscle atrophy, yet the underlying associations remain poorly understood. To address this gap, we integrated two GEO datasets (GSE1428 and GSE25941) for differential expression analysis and applied weighted gene co-expression network analysis (WGCNA) to identify disease-related modules. Cuproptosis-related genes (CRGs) from GeneCards database were intersected with DEGs and WGCNA gene modules to obtain sarcopenia-associated cuproptosis DEGs (SAR-CUP DEGs). Functional enrichment was performed using GO, KEGG, GSEA and GSVA. Hub genes were further identified through three machine learning algorithms (LASSO, RF, and SVM). Regulatory networks were constructed via NetworkAnalyst and GeneMANIA database. A diagnostic model was also developed and later validated in an independent dataset (GSE136344). Experimental validation was performed in a D-galactose-induced sarcopenia cell model. We identified 367 DEGs and 7 co-expression modules, among which 14 SAR-CUP DEGs were mainly enriched in mitochondrial energy metabolism pathways. Machine learning methods highlighted SLC25A12 and PABPC4 as hub genes. Regulatory network analysis revealed key modulators, such as FOXC1, miR-16-5p, GOT2, and GOT1. Diagnostic performance analysis demonstrated strong predictive value for SLC25A12 (AUC = 0.879) and PABPC4 (AUC = 0.858), and RT-qPCR confirmed their downregulation in the sarcopenia cell model (p < 0.01). In conclusion, SLC25A12 and PABPC4 are promising biomarkers linking copper metabolism dysregulation with sarcopenia, offering potential targets for diagnosis and therapy.
- Open Access
- 18 March 2025
- Published by Wiley
Polygonati Rhizoma reduces inflammation and improves muscle atrophy and fibrosis in sarcopenia through the EGFR/MAPK pathway
Polygonati Rhizoma, a traditional Chinese medicine, demonstrates therapeutic potential for sarcopenia, though its bioactive components and mechanisms remain unclear. Ultra-high-performance liquid chromatography-tandem mass spectrometry identified 826 compounds in Polygonati Rhizoma extract(PRE), with Genistein, Camptothecin, and Chrysoeriol highlighted as key bioactive constituents. Network pharmacology analysis revealed critical targets including EGFR, TNF, and CTNNB1, along with associated pathways such as MAPK, IL-17, and TNF signaling. Molecular docking confirmed strong binding affinities between these compounds and targets, with binding energies below -5 kcal/mol. In a D-galactose-induced sarcopenia mouse model, PRE administered at 60 and 120 mg/kg for 8 weeks improved exercise capacity, reduced muscle atrophy and fibrosis through histopathological assessments, and suppressed inflammatory markers. Mechanistic studies demonstrated that the extract enhanced EGFR phosphorylation, activated MAPK signaling, and inhibited TNF and CTNNB1-mediated fibrotic pathways. Pathway analysis further linked these effects to MAPK, IL-17, and TNF signaling cascades, underscoring their roles in mitigating inflammation and fibrosis. This study identifies Genistein, Camptothecin, and Chrysoeriol as pivotal components of Polygonati Rhizoma, acting through multi-target and multi-pathway mechanisms to alleviate sarcopenia. The findings provide a scientific foundation for its clinical application in treating muscle atrophy disorders.
- 18 March 2025
- Published by Wiley
Open AccessPolygonati Rhizoma reduces inflammation and improves muscle atrophy and fibrosis in sarcopenia through the EGFR/MAPK pathway
Polygonati Rhizoma, a traditional Chinese medicine, demonstrates therapeutic potential for sarcopenia, though its bioactive components and mechanisms remain unclear. Ultra-high-performance liquid chromatography-tandem mass spectrometry identified 826 compounds in Polygonati Rhizoma extract(PRE), with Genistein, Camptothecin, and Chrysoeriol highlighted as key bioactive constituents. Network pharmacology analysis revealed critical targets including EGFR, TNF, and CTNNB1, along with associated pathways such as MAPK, IL-17, and TNF signaling. Molecular docking confirmed strong binding affinities between these compounds and targets, with binding energies below -5 kcal/mol. In a D-galactose-induced sarcopenia mouse model, PRE administered at 60 and 120 mg/kg for 8 weeks improved exercise capacity, reduced muscle atrophy and fibrosis through histopathological assessments, and suppressed inflammatory markers. Mechanistic studies demonstrated that the extract enhanced EGFR phosphorylation, activated MAPK signaling, and inhibited TNF and CTNNB1-mediated fibrotic pathways. Pathway analysis further linked these effects to MAPK, IL-17, and TNF signaling cascades, underscoring their roles in mitigating inflammation and fibrosis. This study identifies Genistein, Camptothecin, and Chrysoeriol as pivotal components of Polygonati Rhizoma, acting through multi-target and multi-pathway mechanisms to alleviate sarcopenia. The findings provide a scientific foundation for its clinical application in treating muscle atrophy disorders.
- Open Access
- 27 December 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (52) , e41052
Association between C-reactive protein and sarcopenia: The National Health and Nutrition Examination Survey
C-reactive protein (CRP), a clinical biomarker, is frequently used to evaluate the inflammatory status of the body. However, the association between CRP levels and sarcopenia among the general adult population in the USA is unknown. This study focused on assessing whether CRP levels were associated with sarcopenia. This cross-sectional study collected adult data of adults from the 2015 to 2018 National Health and Nutrition Examination Survey. Four-extremity total muscle mass was used to evaluate sarcopenia (appendicular lean mass). In addition, dual-energy X-ray absorptiometry was adopted to measure appendicular lean mass. The CRP levels were used to assess inflammation status. Odds ratios (OR) and 95% confidence intervals (95% CI) were determined using multivariable logistic regression to analyze the association between CRP levels and sarcopenia. A multivariable-adjusted restricted cubic spline model was built to plot OR curves at 4 knots. Among the 3710 participants involved in this study (average age, 39.4 [11.54] years; 1801 [48.5%] men), 352 (9.5%) displayed characteristics of sarcopenia, while 3358 (90.5%) did not. Compared with participates in the lowest quartile (Q1) of CRP level (Q1; ≤0.08 to ≤0.7), those in the highest quartile (Q4; ≤4.3 to ≤188.5) had an adjusted OR for sarcopenia of 2.74 (95% CI, 1.65–4.57; P < .001). Based on the multivariable restricted cubic spline model, CRP levels showed a nonlinear association with sarcopenia (P < .001). The adjusted OR of sarcopenia of 1.86 (95% CI, 1.37–2.51; P < .001) was determined by 2 piecewise regression models for those having the CRP level of 1.8. Based on subgroup analysis, CRP levels were related to sarcopenia in males (OR, 1.03; 95% CI, 1–1.05) and individuals aged 2 (OR, 1.02; 95% CI, 1–1.03). Our results indicated that CRP levels showed a nonlinear correlation with sarcopenia among adults in the US.
- 27 December 2024
- Published by Wolters Kluwer Health in Medicine
- Vol. 103 (52) , e41052
Open AccessAssociation between C-reactive protein and sarcopenia: The National Health and Nutrition Examination Survey
C-reactive protein (CRP), a clinical biomarker, is frequently used to evaluate the inflammatory status of the body. However, the association between CRP levels and sarcopenia among the general adult population in the USA is unknown. This study focused on assessing whether CRP levels were associated with sarcopenia. This cross-sectional study collected adult data of adults from the 2015 to 2018 National Health and Nutrition Examination Survey. Four-extremity total muscle mass was used to evaluate sarcopenia (appendicular lean mass). In addition, dual-energy X-ray absorptiometry was adopted to measure appendicular lean mass. The CRP levels were used to assess inflammation status. Odds ratios (OR) and 95% confidence intervals (95% CI) were determined using multivariable logistic regression to analyze the association between CRP levels and sarcopenia. A multivariable-adjusted restricted cubic spline model was built to plot OR curves at 4 knots. Among the 3710 participants involved in this study (average age, 39.4 [11.54] years; 1801 [48.5%] men), 352 (9.5%) displayed characteristics of sarcopenia, while 3358 (90.5%) did not. Compared with participates in the lowest quartile (Q1) of CRP level (Q1; ≤0.08 to ≤0.7), those in the highest quartile (Q4; ≤4.3 to ≤188.5) had an adjusted OR for sarcopenia of 2.74 (95% CI, 1.65–4.57; P < .001). Based on the multivariable restricted cubic spline model, CRP levels showed a nonlinear association with sarcopenia (P < .001). The adjusted OR of sarcopenia of 1.86 (95% CI, 1.37–2.51; P < .001) was determined by 2 piecewise regression models for those having the CRP level of 1.8. Based on subgroup analysis, CRP levels were related to sarcopenia in males (OR, 1.03; 95% CI, 1–1.05) and individuals aged 2 (OR, 1.02; 95% CI, 1–1.03). Our results indicated that CRP levels showed a nonlinear correlation with sarcopenia among adults in the US.
- Top Cited PapersOpen Access
- 9 December 2024
- Published by Elsevier in Phytomedicine
- Vol. 136, 156316
Polygonatum sibiricum polysaccharide ameliorates skeletal muscle aging and mitochondrial dysfunction via PI3K/Akt/mTOR signaling pathway
- 9 December 2024
- Published by Elsevier in Phytomedicine
- Vol. 136, 156316
Top Cited PapersOpen AccessPolygonatum sibiricum polysaccharide ameliorates skeletal muscle aging and mitochondrial dysfunction via PI3K/Akt/mTOR signaling pathway
- Open Access
- 21 May 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1363889
Association between the atherogenic index of plasma and bone mineral density among adult women: NHANES (2011–2018)
Background: Studies on the relationship between the atherogenic index of plasma (AIP) and bone mineral density (BMD) among adult women in the United States are limited. The purpose of this study was to explore this association using a sizable, nationally representative sample.Methods: Data from the 2011 to 2018 National Health and Nutrition Examination Survey (NHANES) were used in this observational study. The AIP was computed as log10 (triglycerides/high-density lipoprotein cholesterol). Total BMD was measured via dual-energy X-ray densitometry. We constructed multiple linear regression models to evaluate the correlation between the AIP and BMD. The non-linear relationship was characterized by smooth curve fitting and generalized additive models. We also conducted subgroup and interaction analyses.Results: In this study, we included 2,362 adult women with a mean age of 38.13 ± 12.42 years. The results of multiple linear regression analysis, the AIP and total BMD showed a negative association (β = −0.021, 95%CI: −0.037, −0.006). The curve fitting analysis and threshold effect analysis showed a non-linear relationship between the two variables, and the inflection point of the AIP was found to be -0.61. The total BMD decreased significantly when the AIP reached this value (β = −0.03, 95%CI: −0.04, −0.01). The results of the subgroup analysis showed that AIP and total BMD had a strong negative relationship in participants who were below 45 years old (β = -0.023; 95% CI: -0.041, -0.004), overweight (BMI ≥ 25 kg/m2) (β = -0.022; 95% CI: -0.041, -0.002), had a higher education level (β = -0.025; 95% CI: -0.044, -0.006), and had no partners (β = -0.014; 95% CI: -0.06, -0.009).Conclusions: We found a negative correlation between the AIP and total BMD. Clinicians should pay attention to patients with high AIP, which might indicate a low BMD and has reference significance in preventing osteoporosis.
- 21 May 2024
- Published by Frontiers Media SA in Frontiers in Endocrinology
- Vol. 15, 1363889
Open AccessAssociation between the atherogenic index of plasma and bone mineral density among adult women: NHANES (2011–2018)
Background: Studies on the relationship between the atherogenic index of plasma (AIP) and bone mineral density (BMD) among adult women in the United States are limited. The purpose of this study was to explore this association using a sizable, nationally representative sample.Methods: Data from the 2011 to 2018 National Health and Nutrition Examination Survey (NHANES) were used in this observational study. The AIP was computed as log10 (triglycerides/high-density lipoprotein cholesterol). Total BMD was measured via dual-energy X-ray densitometry. We constructed multiple linear regression models to evaluate the correlation between the AIP and BMD. The non-linear relationship was characterized by smooth curve fitting and generalized additive models. We also conducted subgroup and interaction analyses.Results: In this study, we included 2,362 adult women with a mean age of 38.13 ± 12.42 years. The results of multiple linear regression analysis, the AIP and total BMD showed a negative association (β = −0.021, 95%CI: −0.037, −0.006). The curve fitting analysis and threshold effect analysis showed a non-linear relationship between the two variables, and the inflection point of the AIP was found to be -0.61. The total BMD decreased significantly when the AIP reached this value (β = −0.03, 95%CI: −0.04, −0.01). The results of the subgroup analysis showed that AIP and total BMD had a strong negative relationship in participants who were below 45 years old (β = -0.023; 95% CI: -0.041, -0.004), overweight (BMI ≥ 25 kg/m2) (β = -0.022; 95% CI: -0.041, -0.002), had a higher education level (β = -0.025; 95% CI: -0.044, -0.006), and had no partners (β = -0.014; 95% CI: -0.06, -0.009).Conclusions: We found a negative correlation between the AIP and total BMD. Clinicians should pay attention to patients with high AIP, which might indicate a low BMD and has reference significance in preventing osteoporosis.
- Open Access
- 28 July 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (30) , e34461
Clinical efficacy of botulinum toxin type A in the treatment of fasciitis pain: A systematic review and meta-analysis
Background: The purpose of this meta-analysis was to assess the effectiveness of botulinum toxin type A (BoNT-A) in reducing pain associated with fasciitis. By synthesizing the findings from multiple studies, we aimed to provide a comprehensive evaluation of the current evidence regarding the efficacy of BoNT-A in the treatment of fasciitis pain. Methods: To identify studies for our report, we conducted electronic database searches of Embase, PubMed, Web of Science, and the Cochrane Library from their inception to November 20, 2022. We included only randomized controlled trials that examined the therapeutic effects of BoNT-A on fasciitis pain, with the primary outcome measure being the visual analog scale. We conducted statistical analyses using RevMan 5.4 software. Results: Our final meta-analysis comprised 14 randomized controlled trials involving 537 participants, with 271 patients in the BoNT-A group and 266 patients in the control group. The overall effectiveness of BoNT-A in reducing fasciitis pain was significant, with a mean difference (MD) in visual analog scale score of −2.59 (95% confidence interval [CI], −3.36, −1.82); P < .00001; I 2 = 88%. Subgroup analysis revealed that BoNT-A was particularly effective in treating plantar fasciitis (MD = −3.34 [95% CI, −4.08, −2.78]; P < .00001; I 2 = 75%), lumbar back fasciitis (MD = −2.17 [95% CI, −3.82, −0.52]; P = .001; I 2 = 93%), and neck and shoulder fasciitis (MD = −1.49 [95% CI, −2.76, −0.22]; P = .02; I 2 = 61%). Conclusion: BoNT-A has a significant analgesic effect on fasciitis pain. Therefore, BoNT-A presents a promising alternative treatment option for fasciitis (PROSPERO 2022: CRD42022382805).
- 28 July 2023
- Published by Wolters Kluwer Health in Medicine
- Vol. 102 (30) , e34461
Open AccessClinical efficacy of botulinum toxin type A in the treatment of fasciitis pain: A systematic review and meta-analysis
Background: The purpose of this meta-analysis was to assess the effectiveness of botulinum toxin type A (BoNT-A) in reducing pain associated with fasciitis. By synthesizing the findings from multiple studies, we aimed to provide a comprehensive evaluation of the current evidence regarding the efficacy of BoNT-A in the treatment of fasciitis pain. Methods: To identify studies for our report, we conducted electronic database searches of Embase, PubMed, Web of Science, and the Cochrane Library from their inception to November 20, 2022. We included only randomized controlled trials that examined the therapeutic effects of BoNT-A on fasciitis pain, with the primary outcome measure being the visual analog scale. We conducted statistical analyses using RevMan 5.4 software. Results: Our final meta-analysis comprised 14 randomized controlled trials involving 537 participants, with 271 patients in the BoNT-A group and 266 patients in the control group. The overall effectiveness of BoNT-A in reducing fasciitis pain was significant, with a mean difference (MD) in visual analog scale score of −2.59 (95% confidence interval [CI], −3.36, −1.82); P < .00001; I 2 = 88%. Subgroup analysis revealed that BoNT-A was particularly effective in treating plantar fasciitis (MD = −3.34 [95% CI, −4.08, −2.78]; P < .00001; I 2 = 75%), lumbar back fasciitis (MD = −2.17 [95% CI, −3.82, −0.52]; P = .001; I 2 = 93%), and neck and shoulder fasciitis (MD = −1.49 [95% CI, −2.76, −0.22]; P = .02; I 2 = 61%). Conclusion: BoNT-A has a significant analgesic effect on fasciitis pain. Therefore, BoNT-A presents a promising alternative treatment option for fasciitis (PROSPERO 2022: CRD42022382805).
- 1 October 2021
- Published by Elsevier in World Neurosurgery
- Vol. 154, e222-e235
The Effect of Smoking on the Fusion Rate of Spinal Fusion Surgery: A Systematic Review and Meta-Analysis
- 1 October 2021
- Published by Elsevier in World Neurosurgery
- Vol. 154, e222-e235
The Effect of Smoking on the Fusion Rate of Spinal Fusion Surgery: A Systematic Review and Meta-Analysis
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Effectiveness of Extracorporeal Shock Wave Therapy Reduces Leg Cramps in Patients of Lumbar Degenerative Disorders: A Retrospective Study
Background. The extracorporeal shock wave therapy (ESWT) has been fully utilized in orthopedics, but there are few studies in the treatment of lower limb spasm and pain caused by lumbar degenerative disorders (LDD). This study assesses the influence of ESWT in patients with LDD. Methods. From October 2017 to June 2019, 126 patients with LDD were enrolled. All patients received shock wave therapy, once every two days for four weeks in total. Each treatment consisted of 2,000 shocks with a frequency of 8‐10 shocks per second. To analyze the therapeutic progress, the following tests were performed (before and after therapy; 1‐ and 3‐month follow‐up) to assess pain and functional efficiency: (1) Visual Analog Scale (VAS), (2) the frequency and duration of muscle cramps, and (3) Fugl‐Meyer (LL). Results. Mean BMI of the participants was 26.1 ± 3.0 kg/m2. There was no statistically significant difference in terms of age or BMI between the groups (p > 0.05). Although all scoring parameters improved in both groups, the improvement in the ESWT group was more pronounced in pain (p < 0.001 and p < 0.001, respectively). A review of the LMA scores of our patients demonstrated moderate functional limitations before treatment and increased functional status after treatment in all patients, while overall functional status was fully improved in patients of the ESWT group (p < 0.001). Conclusion. The ESWT is particularly effective effect for patients with LDD. The use of ESWT has a significant long‐term influence on the reduction of pain, leg cramps, and the improvement of the general functional state in relation to the conventional motor improvement program.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessEffectiveness of Extracorporeal Shock Wave Therapy Reduces Leg Cramps in Patients of Lumbar Degenerative Disorders: A Retrospective Study
Background. The extracorporeal shock wave therapy (ESWT) has been fully utilized in orthopedics, but there are few studies in the treatment of lower limb spasm and pain caused by lumbar degenerative disorders (LDD). This study assesses the influence of ESWT in patients with LDD. Methods. From October 2017 to June 2019, 126 patients with LDD were enrolled. All patients received shock wave therapy, once every two days for four weeks in total. Each treatment consisted of 2,000 shocks with a frequency of 8‐10 shocks per second. To analyze the therapeutic progress, the following tests were performed (before and after therapy; 1‐ and 3‐month follow‐up) to assess pain and functional efficiency: (1) Visual Analog Scale (VAS), (2) the frequency and duration of muscle cramps, and (3) Fugl‐Meyer (LL). Results. Mean BMI of the participants was 26.1 ± 3.0 kg/m2. There was no statistically significant difference in terms of age or BMI between the groups (p > 0.05). Although all scoring parameters improved in both groups, the improvement in the ESWT group was more pronounced in pain (p < 0.001 and p < 0.001, respectively). A review of the LMA scores of our patients demonstrated moderate functional limitations before treatment and increased functional status after treatment in all patients, while overall functional status was fully improved in patients of the ESWT group (p < 0.001). Conclusion. The ESWT is particularly effective effect for patients with LDD. The use of ESWT has a significant long‐term influence on the reduction of pain, leg cramps, and the improvement of the general functional state in relation to the conventional motor improvement program.
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Hub Genes and Key Pathways of Intervertebral Disc Degeneration: Bioinformatics Analysis and Validation
Objective. To identify significant pathways and genes in intervertebral disc degeneration (IDD) based on bioinformatics analysis. Design. The GEO database was used to download the GSE124272 dataset. Differentially expressed genes (DEGs) were analyzed using Limma package in R language. Then, gene ontologies (GO), Kyoto encyclopedia of genes and genomes (KEGG), and protein‐protein interaction (PPI) networks were used to further identify hub genes. The mRNA expression levels of top six hub genes were verified. Results. We found 563 DEGs, of which 214 were upregulated and 349 were downregulated. The top 5 GO terms and pathways were shown including immune response, cell cycle, and p53 pathway. Based on the PPI analysis, we verified the mRNA expression levels of 6 hub genes. The mRNA levels of CHEK1, CDCA2, SKA3, and KIF20A were upregulated in degenerative NP tissue than in healthy NP tissue. However, the mRNA level of BUB1 and SPC25 was downregulated. Conclusions. This study may provide new biomarkers for the IDD and treatments to repair IDD related to CHEK1, CDCA2, SKA3, BUB1, KIF20A, and SPC25.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1)
Open AccessHub Genes and Key Pathways of Intervertebral Disc Degeneration: Bioinformatics Analysis and Validation
Objective. To identify significant pathways and genes in intervertebral disc degeneration (IDD) based on bioinformatics analysis. Design. The GEO database was used to download the GSE124272 dataset. Differentially expressed genes (DEGs) were analyzed using Limma package in R language. Then, gene ontologies (GO), Kyoto encyclopedia of genes and genomes (KEGG), and protein‐protein interaction (PPI) networks were used to further identify hub genes. The mRNA expression levels of top six hub genes were verified. Results. We found 563 DEGs, of which 214 were upregulated and 349 were downregulated. The top 5 GO terms and pathways were shown including immune response, cell cycle, and p53 pathway. Based on the PPI analysis, we verified the mRNA expression levels of 6 hub genes. The mRNA levels of CHEK1, CDCA2, SKA3, and KIF20A were upregulated in degenerative NP tissue than in healthy NP tissue. However, the mRNA level of BUB1 and SPC25 was downregulated. Conclusions. This study may provide new biomarkers for the IDD and treatments to repair IDD related to CHEK1, CDCA2, SKA3, BUB1, KIF20A, and SPC25.